Literature DB >> 9140409

A breakpoint map of recurrent chromosomal rearrangements in human neoplasia.

F Mitelman1, F Mertens, B Johansson.   

Abstract

Cytogenetic studies over the past few decades have revealed clonal chromosomal aberrations in almost 27,000 human neoplasms. Many of these neoplasia-associated chromosomal abnormalities have been characterised at the molecular level, revealing previously unknown genes that are closely associated with the tumorigenic process. Information on chromosome changes in neoplasia is growing rapidly, making it difficult to identify all recurrent chromosomal aberrations. We have developed a computer program to ascertain, for the first time, all recurrent structural abnormalities in all haematological malignancies and solid tumours published up to June 1996. Out of 26,523 cases, a total of 215 balanced and 1,588 unbalanced recurrent aberrations were identified among 75 different neoplastic disorders. Our compilation of all recurrent balanced and unbalanced neoplasia-associated rearrangements should help in directing future efforts aimed at identifying the molecular mechanisms involved in tumorigenesis.

Entities:  

Mesh:

Year:  1997        PMID: 9140409     DOI: 10.1038/ng0497supp-417

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  114 in total

1.  Shwachman-Diamond syndrome with exocrine pancreatic dysfunction and bone marrow failure maps to the centromeric region of chromosome 7.

Authors:  S Goobie; M Popovic; J Morrison; L Ellis; H Ginzberg; G R Boocock; N Ehtesham; C Bétard; C G Brewer; N M Roslin; T J Hudson; K Morgan; T M Fujiwara; P R Durie; J M Rommens
Journal:  Am J Hum Genet       Date:  2001-03-15       Impact factor: 11.025

2.  Construction of a high-resolution physical map of the approximate 1-Mb region of human chromosome 7q31.1-q31.2 harboring a putative tumor suppressor gene.

Authors:  J C Zenklusen; L A Weintraub; E D Green
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

3.  MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25).

Authors:  M Osaka; J D Rowley; N J Zeleznik-Le
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

Review 4.  The Cancer Genome Anatomy Project: EST sequencing and the genetics of cancer progression.

Authors:  D B Krizman; L Wagner; A Lash; R L Strausberg; M R Emmert-Buck
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

5.  SMAD5 gene expression, rearrangements, copy number, and amplification at fragile site FRA5C in human hepatocellular carcinoma.

Authors:  Drazen B Zimonjic; Marian E Durkin; Catherine L Keck-Waggoner; Sang-Won Park; Snorri S Thorgeirsson; Nicholas C Popescu
Journal:  Neoplasia       Date:  2003 Sep-Oct       Impact factor: 5.715

6.  Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression.

Authors:  Asa Karlsson; Debabrita Deb-Basu; Athena Cherry; Stephanie Turner; James Ford; Dean W Felsher
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-08       Impact factor: 11.205

Review 7.  The molecular pathology of primary immunodeficiencies.

Authors:  Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Mol Diagn       Date:  2004-05       Impact factor: 5.568

8.  A sparse Ising model with covariates.

Authors:  Jie Cheng; Elizaveta Levina; Pei Wang; Ji Zhu
Journal:  Biometrics       Date:  2014-08-05       Impact factor: 2.571

9.  The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis.

Authors:  Monica Cardone; Ayten Kandilci; Cintia Carella; Jonas A Nilsson; Jennifer A Brennan; Sema Sirma; Ugur Ozbek; Kelli Boyd; John L Cleveland; Gerard C Grosveld
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

10.  Mad2 and p53 expression profiles in colorectal cancer and its clinical significance.

Authors:  Gang-Qiang Li; Hao Li; Hong-Fu Zhang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.